|Bid||0.0700 x N/A|
|Ask||0.0790 x N/A|
|Day's range||0.0750 - 0.0810|
|52-week range||0.0750 - 0.0810|
|Beta (5Y monthly)||-2.39|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
The Directors of Biotron Limited (ASX: BIT) are pleased to announce that the Company's lead clinical asset, BIT225, has demonstrated substantial and clinically meaningful efficacy against SARS-CoV-2 in a series of animal and cell-based studies performed at The SCRIPPS Research Institute, La Jolla, CA, USA.